DFB Pharmaceuticals, Inc. to Receive Exclusive License for U.S. Government-Owned Patent

Summary

The U.S. government has announced its intent to grant an exclusive, royalty-bearing license to DFB Pharmaceuticals, Inc. for the patent 5,607,979, which covers topical skin protectants for preventing or treating contact and allergic dermatitis, as well as dermatitis caused by incontinence.